FR2878522B1 - Nouveaux inhibiteurs specifiques de la caspas-10 - Google Patents

Nouveaux inhibiteurs specifiques de la caspas-10

Info

Publication number
FR2878522B1
FR2878522B1 FR0412765A FR0412765A FR2878522B1 FR 2878522 B1 FR2878522 B1 FR 2878522B1 FR 0412765 A FR0412765 A FR 0412765A FR 0412765 A FR0412765 A FR 0412765A FR 2878522 B1 FR2878522 B1 FR 2878522B1
Authority
FR
France
Prior art keywords
caspas
specific inhibitors
new specific
new
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0412765A
Other languages
English (en)
Other versions
FR2878522A1 (fr
Inventor
Claude Lardy
Marc Lecomte
Catherine Vidal
Thierry Convard
Stephane Yvon
Marie Noelle Denuault
Denis Descours
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0412765A priority Critical patent/FR2878522B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to AU2005312137A priority patent/AU2005312137B2/en
Priority to EP05808239.7A priority patent/EP1817031B1/fr
Priority to JP2007543716A priority patent/JP4989482B2/ja
Priority to PCT/EP2005/011686 priority patent/WO2006058592A1/fr
Priority to US11/791,922 priority patent/US7829721B2/en
Priority to CA2589497A priority patent/CA2589497C/fr
Publication of FR2878522A1 publication Critical patent/FR2878522A1/fr
Application granted granted Critical
Publication of FR2878522B1 publication Critical patent/FR2878522B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/38—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
FR0412765A 2004-12-01 2004-12-01 Nouveaux inhibiteurs specifiques de la caspas-10 Expired - Fee Related FR2878522B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0412765A FR2878522B1 (fr) 2004-12-01 2004-12-01 Nouveaux inhibiteurs specifiques de la caspas-10
EP05808239.7A EP1817031B1 (fr) 2004-12-01 2005-11-02 Inhibiteurs de la caspase-10 pour la prevention et le traitement de la retinopathie
JP2007543716A JP4989482B2 (ja) 2004-12-01 2005-11-02 新規特異的カスパーゼ−１０阻害剤
PCT/EP2005/011686 WO2006058592A1 (fr) 2004-12-01 2005-11-02 Nouveaux inhibiteurs specifiques de la caspase-10
AU2005312137A AU2005312137B2 (en) 2004-12-01 2005-11-02 Novel specific caspase-10 inhibitors
US11/791,922 US7829721B2 (en) 2004-12-01 2005-11-02 Specific caspase-10 inhibitors
CA2589497A CA2589497C (fr) 2004-12-01 2005-11-02 Nouveaux inhibiteurs specifiques de la caspase-10

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0412765A FR2878522B1 (fr) 2004-12-01 2004-12-01 Nouveaux inhibiteurs specifiques de la caspas-10

Publications (2)

Publication Number Publication Date
FR2878522A1 FR2878522A1 (fr) 2006-06-02
FR2878522B1 true FR2878522B1 (fr) 2008-04-18

Family

ID=34953773

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0412765A Expired - Fee Related FR2878522B1 (fr) 2004-12-01 2004-12-01 Nouveaux inhibiteurs specifiques de la caspas-10

Country Status (7)

Country Link
US (1) US7829721B2 (fr)
EP (1) EP1817031B1 (fr)
JP (1) JP4989482B2 (fr)
AU (1) AU2005312137B2 (fr)
CA (1) CA2589497C (fr)
FR (1) FR2878522B1 (fr)
WO (1) WO2006058592A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042652A2 (fr) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
US20110120915A1 (en) * 2009-11-24 2011-05-26 Chevron U.S.A. Inc. Hydrogenation of solid carbonaceous materials using mixed catalysts
CN110542675B (zh) * 2019-09-30 2021-12-14 广州市锐博生物科技有限公司 细胞凋亡检测方法及细胞凋亡检测试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK125461B (da) 1967-12-20 1973-02-26 Ciba Geigy Ag Fremgangsmåde til fremstilling af substituerede phenyleddikesyrer eller salte deraf.
JPS56125339A (en) * 1980-03-07 1981-10-01 Nippon Shinyaku Co Ltd Preparation of phenylacetic acid derivative
JPS56125338A (en) 1980-03-07 1981-10-01 Nippon Shinyaku Co Ltd Phenylacetic acid derivative
JPS56125333A (en) 1980-03-07 1981-10-01 Nippon Shinyaku Co Ltd Phenylacetic acid derivative and its preparation
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
ZA931062B (en) 1992-02-17 1993-08-17 Ciba Geigy Compositions for the treatment of glaucoma.
US6398758B1 (en) * 1999-02-16 2002-06-04 Stephen C. Jacobsen Medicament delivery system
US6304786B1 (en) * 1999-03-29 2001-10-16 Cardiac Pacemakers, Inc. Implantable lead with dissolvable coating for improved fixation and extraction
AU6894800A (en) * 1999-08-06 2001-03-05 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU1920501A (en) 1999-12-03 2001-06-12 Alcon Universal Limited The use of caspase 9 inhibitors to treat ocular neural pathology
WO2001081312A2 (fr) * 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Methode de traitement se basant sur l'utilisation de derives de phenyle et de biaryle comme inhibiteurs de prostaglandine e
FR2815541B1 (fr) 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
US20020103526A1 (en) * 2000-12-15 2002-08-01 Tom Steinke Protective coating for stent
GB2388209C (en) * 2001-12-20 2005-08-23 Canon Kk Control apparatus
US20040034064A1 (en) * 2002-08-06 2004-02-19 Kuduk Scott D. 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives
JP2006507329A (ja) * 2002-11-21 2006-03-02 ニューロサーチ、アクティーゼルスカブ 新規アリールウレイド安息香酸誘導体及びその使用
US7314480B2 (en) * 2003-02-27 2008-01-01 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery
US7284401B2 (en) * 2004-01-12 2007-10-23 Boston Scientific Scimed, Inc. Stent reducing system and device
US7225518B2 (en) * 2004-02-23 2007-06-05 Boston Scientific Scimed, Inc. Apparatus for crimping a stent assembly
US8535702B2 (en) * 2005-02-01 2013-09-17 Boston Scientific Scimed, Inc. Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
US8257727B2 (en) * 2005-07-21 2012-09-04 Fmc Biopolymer As Medical devices coated with a fast dissolving biocompatible coating

Also Published As

Publication number Publication date
EP1817031B1 (fr) 2014-05-21
FR2878522A1 (fr) 2006-06-02
EP1817031A1 (fr) 2007-08-15
WO2006058592A1 (fr) 2006-06-08
CA2589497A1 (fr) 2006-06-08
AU2005312137B2 (en) 2011-05-26
JP2008521841A (ja) 2008-06-26
CA2589497C (fr) 2013-08-20
US7829721B2 (en) 2010-11-09
AU2005312137A1 (en) 2006-06-08
JP4989482B2 (ja) 2012-08-01
US20080255173A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
LTPA2017004I1 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK1720866T3 (da) Fremgangsmåde
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
ITMI20050191A1 (it) Struttura di fet ad alette
DK1802872T3 (da) Rörledning
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1831605T3 (da) Fremgangsmåde vedrørende forbrænding
FR2873694B1 (fr) Nouveaux aza-indoles inhibiteurs de la mtp et apob
NO20043305D0 (no) Preparation of lodixanol
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
FR2884820B1 (fr) Nouveaux inhibiteurs specifiques de la caspase-10
ITMI20041626A1 (it) Inibitori della chinurenina-ammino-trasferasi
FR2878522B1 (fr) Nouveaux inhibiteurs specifiques de la caspas-10
DK1962960T3 (da) Fremgangsmåde til mikornisering
FR2877833B1 (fr) Correcteur de lordoses
ITVR20040028A1 (it) Struttura di longherone
AT7230U3 (de) Wasserpfeife
DOP2004000824A (es) Nuevos derivados de 2-piridinacarboxamida
SE0400113D0 (sv) Methods for protein purification
SE0400528D0 (sv) Methods for protein purification

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140829